Experimental Obesity Drugs Prove Highly Effective in Recent Trials

Novo Nordisk, Eli Lilly and Boehringer Ingelheim have announced promising results from trials of new weight loss drugs, with some leading to loss of 15% of body weight or more.
The experimental drugs, known as GLP-1 receptor agonists, work by mimicking hormones to reduce appetite, slow stomach emptying and lower blood sugar.
Novo Nordisk's semaglutide pill led to 15.1% weight loss in a trial, while its injected drugs Ozempic and Wegovy have also shown strong results.
Eli Lilly's experimental pill led to nearly 15% weight loss in a mid-stage trial, while its injected drug Mounjaro helped patients lose 15% of their body weight.
Boehringer Ingelheim and Zealand Pharma's obesity treatment reduces body weight by up to 19% in a mid-stage trial.